Q1 rev $8.9M (+2%); net loss $5.1M; DrugSorb-ATR FDA submission delayed to late 2026/early 2027

Cytosorbents Corp

2026-Q1 EPS reported -$0.08 vs consensus -$0.06 ▼ miss (-42.6%)

Revenue $8.9M, +2% YoY; gross margin 69% vs 71% in Q1 2025.
Net loss $5.1M ($0.08/share) vs $1.5M ($0.02) in Q1 2025, driven by non-cash FX; adjusted net loss improved to $3.4M ($0.05).
Cash $6.4M vs $7.8M Dec 31; cash burn $1.1M (excl. $0.3M restructuring); targeting operating cash flow breakeven H2 2026.
DrugSorb-ATR for Brilinta: new De Novo submission delayed to late 2026/early 2027 after FDA requested additional mechanistic data.
Distributor orders delayed ~$500k in Middle East due to U.S.-Iran war; Germany direct sales slightly down but with smaller team.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.